FDA issues how-to on drug-shortage management; Opioid debate may be hurting end-of-life patients;

@FiercePharma: Top-read in FiercePharmaManufacturing Thursday: $ACT production not meeting demand for new version of Alzheimer's drug. Article | Follow @FiercePharma

@EricPFierce: Analysts propose hookups for troubled Wockhardt even though execs insist it is not for sale. More | Follow @EricPFierce

@CarlyHFierce: Legendary Genentech CEO Levinson cuts last ties with Roche. Story | Follow @CarlyHFierce

> The FDA has issued a new 24-page MAPP for how to report and manage drug shortages. MAPP (PDF)

> The U.S. and the EU have added $250 million to the pot to fight the Ebola outbreak after the World Health Organization said it had been hampered by budget cuts. Story

> Dutch civil servants decided to withhold from parliament information about negotiations it was having with drugmakers, including Boehringer Ingelheim. Story

Medical Device News

@FierceMedDev: Myriad's multigene predictive cancer test shows utility in new trial. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: The metal-on-metal hip legal saga round one (of 6,000?): J&J vs. Herlihy-Paoli. Story | Follow @VarunSaxena2

@MichaelGFierce: ICYMI: Artificial virus promises effective drug delivery and gene therapy. FierceDrugDelivery article | Follow @MichaelGFierce

@EmilyWFierce: Case hedges bets on brain device developer with a smartphone-based system for traumatic brain injuries. More from Bloomberg | Follow @EmilyWFierce

> Israeli colon capsule maker bucks M&A trend with plans for $60M IPO. News

> Researchers diagnose atrial fibrillation via webcam. Story

Biotech News

@FierceBiotech: EuroBiotech Report: AZ strikes Alderley cancer pact, Cerenis mulls IPO, 4D to start microbiome trials in 2015, more. More | Follow @FierceBiotech

@JohnCFierce: ICYMI - Merck wins breakthrough FDA approval for blockbuster cancer contender pembrolizumab. Report | Follow @JohnCFierce

@DamianFierce: $KMDA won't let a little thing like missing its endpoints in PhII/III derail a regulatory filing. ICYMI yesterday | Follow @DamianFierce

@EmilyMFierce: FDA rushes J&J, NewLink Ebola vaccines to clinical trials. FierceVaccines story | Follow @EmilyMFierce

> Recro tanks after hitting the brakes on its lead pain drug. Story

> OncoMed gets back on track as FDA clears another clinical hold. Article

> Merck wins breakthrough FDA approval for blockbuster cancer contender pembrolizumab. News

And Finally... A study suggests that the debate over opioids has kept some cancer patients from getting them even as their death nears. Story

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.